mumbai shares dropped much 636 bse thursday us drug regulator issued import alert karkhadi plant gujarat banning shipments factory makes pharma ingredients formulations us market
factory near vadodara gujarat makes small quantity antibiotics got import alert thursday said person familiar development revenue impact negligible
falling low 56560 bse intratrading shares closed 503 lower 57360 day exchanges benchmark sensex fell 037 2177461 points
contribution karkhadi facility near vadodara sun pharmas consolidated revenue negligible drug maker maintains 201314 fiscals consolidated sales growth forecast sun pharma spokesman said statement
company remains fully committed compliance already initiated several corrective steps address observations made us fda food drug administration spokesperson said
sun pharma manufactures active pharma ingredients formulations karkhadi unit drug maker operates 12 usapproved factoriesÂªsix us three india one canada israel hungry sufficient manufacturing capacity serve export markets
thus company well diversified manufacturing infrastructure cater us markets contribute around 54 sales said sector analyst
sun pharmas subsidiaries including recently acquired among others currently account major chunk sales growth
estimate impact import alert sun pharmas karkhadi plant less 1 suns total sales said sector analyst
however note suns premium valuations yield limited downside support operational risks become repetitive
fda alert sun pharmas karkhadi plant followup observations last inspection regulator december related noncompliance current good manufacturing practices
sun pharma resolved much larger issue similar nature us factory belonging subsidiary caraco 2013 nearly sixyear long compliance exercise first fda action facing india several years
us regulator expanded inspection network india adding people team also initiating surprise inspections issued import alerts least half dozen drug manufacturing units last couple years
indias largest drug maker worst hit fda actions recent past us drug regulator banned exportoriented formulation unit mohali active ingredients factory toansa punjab last seven months
ranbaxy signed consent decree us drug regulator become compliant quality regulations two larger indian factories located poanta sahib dewas himachal pradesh madhya pradesh respectively import ban since 2008
also paid penalty 500 million us department justice 2012 company charged fabrication documents selling adulterated drugs american market ranbaxy lost nearly 1 billion us business annually since 2010 regulatory issues
